150
Participants
Start Date
October 31, 2008
Primary Completion Date
October 31, 2010
Study Completion Date
December 31, 2013
2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System
Treatment of a maximum of two de novo native coronary artery lesions in small vessels.
Gotham Cardiovascular Reasearch, PC. (St. Vincent's Medical Center-closing, pts moved), New York
Geisinger Medical Center, Danville
Washington Hospital Center, Washington D.C.
St. Joseph Medical Center, Towson
Union Memorial Hospital, Baltimore
Johns Hopkins Hospital, Baltimore
Forsyth Medical Center, Winston-Salem
WakeMed Hospital, Raleigh
Carolinas Medical Center, Charlotte
Presbyterian Hospital, Charlotte
Morton Plant Hospital, Clearwater
Baptist West Hospital, Knoxville
Riverside Methodist Hospital, Columbus
St. Vincent Mercy Medical Center, Toledo
EMH Regional Medical Center, Elyria
University Hospitals Case Medical Center, Cleveland
The Christ Hospital, Cincinnati
St. Joseph Mercy Hospital, Ypsilanti
Northern Michigan Hospital, Petoskey
St. Cloud Hospital, Saint Cloud
Sanford USD Medical Center, Sioux Falls
St. Patrick Hospital, Missoula
St. Anthony Hospital, Rockford
St. John's Hospital / Prairie Education & Research Cooperative, Springfield
Arkansas Heart Hospital, Little Rock
Hillcrest Medical Center, Tulsa
Mother Frances Hospital, Tyler
Northwest Texas Healthcare System, Amarillo
Scottsdale Healthcare, Scottsdale
Overlake Hospital Medical Center, Bellevue
St. Joseph Hospital, Bellingham
Sacred Heart Hospital, Pensacola
Baystate Medical Center, Springfield
Cooper Health System, Camden
Lead Sponsor
Abbott Medical Devices
INDUSTRY